8-K Announcements
6Material company update
Mar 30, 2026·SEC
Material company update
Mar 19, 2026·SEC
Material company update
Jan 9, 2026·SEC
Alumis Inc. Common Stock(ALMS)Earnings, Financials & Key Ratios
ALMS•NASDAQ
$26.13
$3.07B mkt cap·Price updated May 6, 2026
AboutAlumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. It develops ESK-001, an allosteric tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis, systemic lupus erythematosus, and non-infectious uveitis; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor for neuroinflammatory and neurodegenerative diseases. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. The company was incorporated in 2021 and is headquartered in South San Francisco, California.Show more
- Revenue$24M
- EBITDA-$454M-52.5%
- Net Income-$243M+17.3%
- EPS (Diluted)-2.86+72.4%
- EBITDA Margin-1886.92%
- Operating Margin-1886.92%
- Net Margin-1011.75%
- ROE-86.69%+23.4%
- ROIC-184.05%
- Debt/Equity0.12+3.7%
ALMS Key Insights
Alumis Inc. Common Stock (ALMS) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Momentum leader: RS Rating 98 (top 2%)
- ✓High quality earnings: Operating CF exceeds net income
✗Weaknesses
- ✗Weak Piotroski F-Score: 3/9
- ✗Negative free cash flow
- ✗Shares diluted 100.0% in last year
- ✗Expensive at 73.7x book value
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
ALMS Price & Volume
Alumis Inc. Common Stock (ALMS) stock price & volume — 10-year historical chart
Loading chart...
ALMS Growth Metrics
Alumis Inc. Common Stock (ALMS) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-2.67%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM14.25%
Return on Capital
10 Years-156.37%
5 Years-156.37%
3 Years-168.47%
Last Year-144.36%
ALMS Recent Earnings
Alumis Inc. Common Stock (ALMS) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 2/12 qtrs (29%)●Beat Revenue 2/12 qtrs (40%)
Q2 2026Latest
Mar 19, 2026EPS
$0.95
Est $0.97
+2.1%
Revenue
$2M
Est $2M
-18.4%
Q4 2025
Nov 13, 2025EPS
$1.06
Est $0.92
-15.2%
Revenue
$2M
Est $3M
-24.9%
Q3 2025
Aug 13, 2025EPS
$1.17
Est $1.11
-5.4%
Revenue
$3M
Est $3M
-15.2%
Q2 2025
May 14, 2025EPS
$1.82
Est $1.47
-23.8%
Revenue
$17M
Est $2M
+943.3%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Mar 19, 2026 | $0.95vs $0.97+2.1% | $2Mvs $2M-18.4% |
| Q4 2025 | Nov 13, 2025 | $1.06vs $0.92-15.2% | $2Mvs $3M-24.9% |
| Q3 2025 | Aug 13, 2025 | $1.17vs $1.11-5.4% | $3Mvs $3M-15.2% |
| Q2 2025 | May 14, 2025 | $1.82vs $1.47-23.8% | $17Mvs $2M+943.3% |
Based on last 12 quarters of dataView full earnings history →
ALMS Peer Comparison
Alumis Inc. Common Stock (ALMS) competitors in Immunology and Inflammation Therapies — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 ABBV | 364.63B | 206.15 | 86.98 | 8.57% | 6.91% | 62.15% | 4.89% | |
 CLDX | 2.25B | 33.86 | -8.68 | -78.63% | -172.53% | -49.09% | 0.00 | |
 ARVN | 678.63M | 10.61 | -8.29 | -0.3% | -30.77% | -14.25% | 0.02 | |
 IMVT | 5.66B | 27.84 | -10.20 | -47.07% | 0.00 | |||
 VTRS | 17.87B | 15.52 | -5.17 | -2.98% | -24.58% | -23.89% | 10.84% | 0.98 |
 PFE | 150.4B | 26.44 | 19.44 | -1.65% | 11.83% | 8.34% | 6.03% | 0.78 |
 JNJ | 543.64B | 225.59 | 38.96 | 4.3% | 27.26% | 31.69% | 3.65% | 0.51 |
 BMY | 116.22B | 56.92 | 16.50 | -0.22% | 15.01% | 38.96% | 11.05% | 2.55 |
Compare ALMS vs Peers
Alumis Inc. Common Stock (ALMS) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
ALMS Income Statement
Alumis Inc. Common Stock (ALMS) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 | 24.05M | 22.12M |
| Revenue Growth % | - | - | - | - | - |
| Cost of Goods Sold | 250K | 0 | 3.15M | 0 | 1.74M |
| COGS % of Revenue | - | - | - | - | - |
| Gross Profit | -250K▲ 0% | 0▲ 100.0% | -3.15M▲ 0% | 0▲ 100.0% | 21.3M▲ 0% |
| Gross Margin % | - | - | - | - | 96.29% |
| Gross Profit Growth % | - | 100% | - | 100% | - |
| Operating Expenses | 113.6M | 158.17M | 297.6M | 477.85M | 477.28M |
| OpEx % of Revenue | - | - | - | 1986.92% | - |
| Selling, General & Admin | 12.55M | 20.5M | 35.2M | 91.86M | 74.69M |
| SG&A % of Revenue | - | - | - | 381.94% | - |
| Research & Development | 101.05M | 137.68M | 265.55M | 386M | 389.6M |
| R&D % of Revenue | - | - | - | 1604.98% | - |
| Other Operating Expenses | 0 | 0 | -3.15M | 0 | 1000K |
| Operating Income | -113.85M▲ 0% | -158.17M▼ 38.9% | -300.75M▼ 90.1% | -453.8M▼ 50.9% | -455.98M▲ 0% |
| Operating Margin % | - | - | - | -1886.92% | -2061.3% |
| Operating Income Growth % | - | -38.93% | -90.14% | -50.89% | - |
| EBITDA | -113.6M | -156.89M | -297.6M | -453.8M | -452.53M |
| EBITDA Margin % | - | - | - | -1886.92% | -2045.71% |
| EBITDA Growth % | - | -38.11% | -89.69% | -52.49% | -89.18% |
| D&A (Non-Cash Add-back) | 250K | 1.28M | 3.15M | 0 | 3.45M |
| EBIT | -113.85M | -158.17M | -300.75M | 0 | -427.88M |
| Net Interest Income | 1.99M | 3.37M | 12.02M | 0 | 14.5M |
| Interest Income | 1.99M | 3.37M | 12.02M | 14.18M | 14.5M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income/Expense | 1.92M | 3.18M | 6.52M | 201.92M | 202.27M |
| Pretax Income | -111.93M▲ 0% | -154.99M▼ 38.5% | -294.23M▼ 89.8% | -251.89M▲ 14.4% | -253.71M▲ 0% |
| Pretax Margin % | - | - | - | -1047.34% | -1146.94% |
| Income Tax | 0 | 0 | 0 | -8.56M | -8.56M |
| Effective Tax Rate % | 0% | 0% | 0% | 3.4% | 3.37% |
| Net Income | -111.93M▲ 0% | -154.99M▼ 38.5% | -294.23M▼ 89.8% | -243.32M▲ 17.3% | -245.15M▲ 0% |
| Net Margin % | - | - | - | -1011.75% | -1108.24% |
| Net Income Growth % | - | -38.47% | -89.84% | 17.3% | -2.67% |
| Net Income (Continuing) | -111.93M | -154.99M | -294.23M | -243.32M | -245.15M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -14.93▲ 0% | -2.99▲ 80.0% | -10.38▼ 247.2% | -2.86▲ 72.4% | -2.35▲ 0% |
| EPS Growth % | - | 79.97% | -247.16% | 72.45% | 14.25% |
| EPS (Basic) | -14.93 | -2.99 | -10.38 | -2.86 | - |
| Diluted Shares Outstanding | 7.5M | 51.84M | 28.34M | 850.3M | 104.11M |
| Basic Shares Outstanding | 7.5M | 51.84M | 28.34M | 850.3M | 104.11M |
| Dividend Payout Ratio | - | - | - | - | - |
ALMS Balance Sheet
Alumis Inc. Common Stock (ALMS) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|
| Total Current Assets | 102.56M | 53.36M | 306.19M | 318.23M | 393.29M |
| Cash & Short-Term Investments | 92.86M | 48.95M | 288.26M | 308.5M | 377.72M |
| Cash Only | 25.61M | 46M | 169.53M | 89.67M | 65.26M |
| Short-Term Investments | 67.25M | 2.96M | 118.74M | 218.83M | 312.47M |
| Accounts Receivable | 500K | 722K | 1.81M | 0 | 3.64M |
| Days Sales Outstanding | - | - | - | - | 60.2 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - |
| Other Current Assets | 206K | 208K | 762K | 9.73M | 1M |
| Total Non-Current Assets | 5.61M | 36.26M | 34.8M | 93.71M | 94.72M |
| Property, Plant & Equipment | 4.47M | 35.22M | 33.69M | 35.16M | 36.57M |
| Fixed Asset Turnover | - | - | - | 0.68x | 0.62x |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 50.96M | 50.96M |
| Long-Term Investments | 0 | 0 | 0 | 0 | 1.37M |
| Other Non-Current Assets | 1.14M | 1.03M | 1.11M | 7.59M | 12M |
| Total Assets | 108.17M▲ 0% | 89.61M▼ 17.2% | 340.99M▲ 280.5% | 411.94M▲ 20.8% | 488.01M▲ 0% |
| Asset Turnover | - | - | - | 0.06x | 0.05x |
| Asset Growth % | - | -17.15% | 280.52% | 20.81% | 476.51% |
| Total Current Liabilities | 13.35M | 20.87M | 50.91M | 73.32M | 65.42M |
| Accounts Payable | 1.72M | 1.12M | 9.62M | 10.11M | 4.55M |
| Days Payables Outstanding | 2.51K | - | 1.11K | - | 1.93K |
| Short-Term Debt | 0 | 0 | 0 | 4.67M | 0 |
| Deferred Revenue (Current) | 0 | 0 | 0 | 1.46M | 0 |
| Other Current Liabilities | 3.58M | 5.58M | 7.76M | 67.19M | 44.28M |
| Current Ratio | 7.68x | 2.56x | 6.01x | 4.34x | 4.34x |
| Quick Ratio | 7.68x | 2.56x | 6.01x | 4.34x | 4.34x |
| Cash Conversion Cycle | - | - | - | - | -1.87K |
| Total Non-Current Liabilities | 290.06M | 408M | 29.98M | 37.33M | 37.83M |
| Long-Term Debt | 0 | 0 | 0 | 32.24M | 0 |
| Capital Lease Obligations | 469K | 30.86M | 29.16M | 0 | 126.6M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 2.14M | 4.28M |
| Other Non-Current Liabilities | 289.59M | 377.14M | 814K | 2.94M | 2.31M |
| Total Liabilities | 303.41M | 428.87M | 80.89M | 110.64M | 103.24M |
| Total Debt | 1.78M | 32.58M | 30.72M | 36.91M | 37.8M |
| Net Debt | -23.83M | -13.42M | -138.8M | -52.76M | -27.46M |
| Debt / Equity | - | - | 0.12x | 0.12x | 0.12x |
| Debt / EBITDA | - | - | - | - | -0.08x |
| Net Debt / EBITDA | - | - | - | - | 0.06x |
| Interest Coverage | - | - | - | - | - |
| Total Equity | -195.24M▲ 0% | -339.26M▼ 73.8% | 260.1M▲ 176.7% | 301.3M▲ 15.8% | 384.77M▲ 0% |
| Equity Growth % | - | -73.76% | 176.67% | 15.84% | 541.34% |
| Book Value per Share | -26.04 | -6.54 | 9.18 | 0.35 | 3.70 |
| Total Shareholders' Equity | -195.24M | -339.26M | 260.1M | 301.3M | 384.77M |
| Common Stock | 1K | 1K | 4K | 9K | 10K |
| Retained Earnings | -209.32M | -364.32M | -658.55M | -901.88M | -808.95M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -127K | 2K | 40K | 188K | 234K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
ALMS Cash Flow Statement
Alumis Inc. Common Stock (ALMS) cash flow — operating, investing & free cash flow history
| Line item | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|
| Cash from Operations | -107.72M | -129.97M | -255.08M | -369.52M | -369.52M |
| Operating CF Margin % | - | - | - | -1536.48% | - |
| Operating CF Growth % | - | -20.66% | -96.25% | -44.87% | -339.03% |
| Net Income | -111.93M | -154.99M | -294.23M | -243.32M | -245.15M |
| Depreciation & Amortization | 250K | 1.28M | 3.15M | 3.5M | 3.45M |
| Stock-Based Compensation | 5.96M | 8.63M | 19.46M | 43.52M | 16.14M |
| Deferred Taxes | 0 | 0 | 0 | -8.56M | 0 |
| Other Non-Cash Items | -86K | 3.05M | 1.79M | -164.66M | -166.13M |
| Working Capital Changes | -1.92M | 12.06M | 14.76M | 0 | 19.31M |
| Change in Receivables | 0 | 0 | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 1.29M | -642K | 8.51M | -6.04M | -10.42M |
| Cash from Investing | -68.75M | 60.47M | -113.79M | 287.88M | 223.81M |
| Capital Expenditures | -2.41M | -4.5M | -1.73M | -653K | -1.02M |
| CapEx % of Revenue | - | - | - | 2.72% | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 49.74M | 49.74M |
| Cash from Financing | 101.63M | 89.68M | 492.37M | 2.07M | 754K |
| Debt Issued (Net) | 0 | 0 | 0 | 0 | 0 |
| Equity Issued (Net) | 1000K | 1000K | 1000K | 0 | 771K |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 1.73M | -96K | 40.59M | 2.07M | -17K |
| Net Change in Cash | -74.85M▲ 0% | 20.18M▲ 127.0% | 123.5M▲ 512.0% | -79.58M▼ 164.4% | -148.17M▲ 0% |
| Free Cash Flow | -110.13M▲ 0% | -134.47M▼ 22.1% | -256.81M▼ 91.0% | -370.18M▼ 44.1% | -373.4M▲ 0% |
| FCF Margin % | - | - | - | -1539.19% | -1687.98% |
| FCF Growth % | - | -22.11% | -90.97% | -44.14% | -72.38% |
| FCF per Share | -14.69 | -2.59 | -9.06 | -0.44 | -0.44 |
| FCF Conversion (FCF/Net Income) | 0.96x | 0.84x | 0.87x | 1.52x | 1.52x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 |
ALMS Key Ratios
Alumis Inc. Common Stock (ALMS) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|
| Return on Equity (ROE) | - | -113.12% | -86.69% | -75.52% |
| Return on Invested Capital (ROIC) | - | - | -184.05% | -184.05% |
| Gross Margin | - | - | - | 96.29% |
| Net Margin | - | - | -1011.75% | -1108.24% |
| Debt / Equity | - | 0.12x | 0.12x | 0.12x |
| FCF Conversion | 0.84x | 0.87x | 1.52x | 1.52x |
ALMS SEC Filings & Documents
Alumis Inc. Common Stock (ALMS) SEC filings — annual & quarterly reports (10-K, 10-Q)
ALMS Frequently Asked Questions
Alumis Inc. Common Stock (ALMS) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Alumis Inc. Common Stock (ALMS) reported $22.1M in revenue for fiscal year 2025.
Alumis Inc. Common Stock (ALMS) grew revenue by 0.0% over the past year. Growth has been modest.
Alumis Inc. Common Stock (ALMS) reported a net loss of $245.2M for fiscal year 2025.
Dividend & Returns
Alumis Inc. Common Stock (ALMS) has a return on equity (ROE) of -86.7%. Negative ROE indicates the company is unprofitable.
Alumis Inc. Common Stock (ALMS) had negative free cash flow of $373.4M in fiscal year 2025, likely due to heavy capital investments.
Explore More ALMS
Alumis Inc. Common Stock (ALMS) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates